Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Inclusion Criteria:

* Age ≥ 18 years
* Provision of written informed consent
* Histologically or cytologically documented advanced or metastatic solid tumor that is refractory to standard treatment, for which no standard therapy is available, or for which the subject refuses standard therapy
* Life expectancy \> 3 months in the opinion of the investigator
* ECOG performance status 0 to 1
* Evaluable OR measurable disease by RECIST 1.1 criteria
* Agree to the use of effective contraceptive if either male or female of child bearing potential

Exclusion Criteria:

* Inadequate venous access
* Women who are lactating/breastfeeding
* Women with a positive pregnancy test or who are planning to become pregnant during the duration of the study
* Known to be HIV positive, or have chronic hepatitis B or C
* Major surgical procedure within 6 weeks of Baseline or surgical or other wound that is not fully healed at Baseline
* Untreated or symptomatic brain metastasis, known central nervous system metastasis, or spinal cord compression (except glioblastoma multiforme)
* Mediastinal or cavitated, or lung mass located near, invading or encasing a major blood vessel or airway on imaging
* Squamous cell lung cancer
* History of or known/suspected gastrointestinal perforation
* Hemoptysis of \>2.5 mL (half a teaspoon) red blood within 28 days of Screening
* Deep venous thrombosis or history of symptomatic pulmonary thromboembolism within 6 months of Screening
* Gastrointestinal bleeding requiring medical intervention within 28 days of Screening
* Receipt of therapeutic concentrations of warfarin or other anticoagulants within 7 days of Screening
* Receipt of investigational agent(s) for any indication within 28 days of Baseline or 5 half lives, whichever is greater
* Receipt of the following treatments:

  * Traditional cytotoxics, tyrosine kinase inhibitors or other small molecule anti-cancer agents within 21 days
  * Nitrosoureas, mitomycin C, bevacizumab or trastuzumab within 6 weeks
  * Any other therapeutic monoclonal antibodies within 21 days
  * Hormonal therapy (other than gonadal suppression) within 14 days
* Radiotherapy:

  * to \>25% bone marrow
  * to brain within 28 days of baseline
  * other than above within 14 days of baseline
* Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of Screening
* History of CNS hemorrhage, cerebrovascular hemorrhage, myocardial infarction or reversible posterior leukoencephalopathy syndrome associated with prior anti-VEGF/anti-VEGFR therapy
* Uncontrolled hypertension of ≥ CTCAE Grade 2
* Proteinuria at Baseline of ≥2+ or 1.0g/24 hours
* Prior allergic reaction to a monoclonal antibody